buy only 94.5Buy only above 94.5
T1: 101.5
T2:------------ 121.5
T3-------------------- 135
STOPLOSS:------------------------- 86.25
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.42EUR
−459.33 MEUR
225.94 MEUR
61.28 M
About Blueprint Medicines Corporation
Sector
Industry
CEO
Kathryn Haviland
Website
Headquarters
Cambridge
Employees (FY)
655
Founded
2008
FIGI
BBG008ML55V0
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 2L9 is 99.74 EUR — it has decreased by 1.25% in the past 24 hours. Watch BLUEPRINT MEDICINES CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange BLUEPRINT MEDICINES CORP stocks are traded under the ticker 2L9.
2L9 stock has risen by 2.21% compared to the previous week, the month change is a 7.25% rise, over the last year BLUEPRINT MEDICINES CORP has showed a 67.63% increase.
We've gathered analysts' opinions on BLUEPRINT MEDICINES CORP future price: according to them, 2L9 price has a max estimate of 156.00 EUR and a min estimate of 69.64 EUR. Watch 2L9 chart and read a more detailed BLUEPRINT MEDICINES CORP stock forecast: see what analysts think of BLUEPRINT MEDICINES CORP and suggest that you do with its stocks.
2L9 stock is 4.72% volatile and has beta coefficient of 1.05. Track BLUEPRINT MEDICINES CORP stock price on the chart and check out the list of the most volatile stocks — is BLUEPRINT MEDICINES CORP there?
Today BLUEPRINT MEDICINES CORP has the market capitalization of 6.31 B, it has decreased by 0.50% over the last week.
Yes, you can track BLUEPRINT MEDICINES CORP financials in yearly and quarterly reports right on TradingView.
BLUEPRINT MEDICINES CORP is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
2L9 earnings for the last quarter are 1.34 EUR per share, whereas the estimation was −1.54 EUR resulting in a 187.01% surprise. The estimated earnings for the next quarter are −1.21 EUR per share. See more details about BLUEPRINT MEDICINES CORP earnings.
BLUEPRINT MEDICINES CORP revenue for the last quarter amounts to 89.08 M EUR, despite the estimated figure of 74.97 M EUR. In the next quarter, revenue is expected to reach 95.94 M EUR.
2L9 net income for the last quarter is 82.61 M EUR, while the quarter before that showed −100.49 M EUR of net income which accounts for 182.20% change. Track more BLUEPRINT MEDICINES CORP financial stats to get the full picture.
No, 2L9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 30, 2024, the company has 655.00 employees. See our rating of the largest employees — is BLUEPRINT MEDICINES CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BLUEPRINT MEDICINES CORP EBITDA is −392.54 M EUR, and current EBITDA margin is −190.32%. See more stats in BLUEPRINT MEDICINES CORP financial statements.
Like other stocks, 2L9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BLUEPRINT MEDICINES CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BLUEPRINT MEDICINES CORP technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BLUEPRINT MEDICINES CORP stock shows the strong buy signal. See more of BLUEPRINT MEDICINES CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.